EDUCATION

Tumor Mutational Burden: Diagnostic Innovations and Clinical Implications

While TMB has emerged as a biomarker with potential relevance to many tumor types, significant uncertainty remains regarding the overall utility of TMB testing.  Building on the 2018 webinar series, “Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care”, this new two-part series will provide up-to-date information surrounding TMB testing in the laboratory and utility in clinic.

This upcoming TMB series, slated to focus on diagnostic innovations and clinical implications, will address two issues.  First, it will provide an update on what has evolved in the TMB space within the past year, including testing harmonization efforts and recent data regarding the use of TMB as a predictive biomarker.  Secondly, it will examine the role of TMB testing in the larger landscape of biomarkers that can be used to assess response to immunotherapy. 

 

Webinar #1: Updates on Tumor Mutational Burden and the Immunotherapy Biomarker Landscape

     Speaker: Laura Tafe, MD

     Recorded: Thursday, June 6, 2019

    Access On-Demand Webinar

 

Webinar #2: Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation

     Speaker: Albrecht Stenzinger, MD

     Recorded: Thursday, August 15, 2019

     Access On-Demand Webinar

 

This webinar series on Tumor Mutational Burden (TMB II) was planned and coordinated by the TMB II Faculty:
 

Jonathan Nowak, MD, PhD, Content Chair
Brigham & Women’s Hospital

Laura J. Tafe, MD
Dartmouth-Hitchcock Health System

Albrecht Stenzinger, MD
University Hospital Heidelberg, Germany


and supported by the Training & Education Committee (Cecilia C.S. Yeung, MD, Chair)

  

This program has been supported through an educational grant from Bristol-Myers Squibb.

Instructions for Accessing Live, Archived, and On-Demand Webinars from AMP

 


IC-Onc LogoAMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.

 


 

Join us for this free online learning experience exploring how measuring tumor mutational burden can improve patient care. 

 

This webinar series on Tumor Mutational Burden (TMB) was planned and coordinated by the TMB Content Committee:
 

Susan Hsiao, MD, PhD Chair
New York Presbyterian/Columbia University

Jonathan Nowak, MD, PhD
Brigham & Women’s Hospital

Jeremy Segal MD, PhD
University of Chicago


and supported by the Training & Education Committee (Cecilia C.S. Yeung, MD, Chair)

 

 

This program has been supported through an educational grant from Bristol-Myers Squibb.

Instructions for Accessing Live, Archived, and On-Demand Webinars from AMP

Download Flyer

 


IC-Onc LogoAMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.

 

Corporate Partners